EcoDrugPlus

Calcium Channel, Voltage-Dependent, L Type, Alpha 1f Subunit

Ensembl ID : ENSMAMG00000012089
Gene Symbol: CACNA1FB
2 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, A

Ensembl ID : ENSMAMG00000018547
Gene Symbol: CACNA1BA
3 Cross references
219 Possible Orthologues:

Calcium Channel, Voltage-Dependent, N Type, Alpha 1b Subunit, B

Ensembl ID : ENSMAMG00000002192
Gene Symbol: CACNA1BB
2 Cross references
218 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSMAMG00000003922
Gene Symbol: CACNA1AB
3 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, T Type, Alpha 1g Subunit

Ensembl ID : ENSMAMG00000000982
Gene Symbol: CACNA1G
2 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1a

Ensembl ID : ENSMAMG00000011694
Gene Symbol: CACNA2D1A
3 Cross references
226 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 2a

Ensembl ID : ENSMAMG00000016468
Gene Symbol: CACNA2D2A
3 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 1 Subunit

Ensembl ID : ENSMAMG00000022167
Gene Symbol: CACNB1
3 Cross references
209 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3a

Ensembl ID : ENSMAMG00000024145
Gene Symbol: CACNB3A
3 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 3b

Ensembl ID : ENSMAMG00000004086
Gene Symbol: CACNB3B
2 Cross references
198 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 2a

Ensembl ID : ENSMAMG00000020720
Gene Symbol: CACNG2A
3 Cross references
205 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 3b

Ensembl ID : ENSMAMG00000004102
Gene Symbol: CACNG3B
2 Cross references
179 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).